PBT2

PBT2
Names
	IUPAC name 5,7-Dichloro-2-[(dimethylamino)methyl]quinolin-8-ol
Identifiers
3D model (JSmol)	Interactive image;
ChemSpider	8191585;
PubChem CID	10016012;
UNII	Q7K6GJQ4O4 ;
CompTox Dashboard (EPA)	DTXSID701029571 ;
	InChI InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3 Key: YZPOQCQXOSEMAZ-UHFFFAOYSA-N;
	SMILES CN(C)CC1=NC2=C(C=C1)C(=CC(=C2O)Cl)Cl;
Properties
Chemical formula	C12H12Cl2N2O
Molar mass	271.14 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

PBT2 is an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog^[1] intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease.^[2]

Clinical trials

PBT2 was the subject of phase II clinical trials for Alzheimer's disease and Huntington's disease. The results for Alzheimer's disease failed to meet its goals,^[3]^[4] and there is no evidence that PBT2 is of any benefit in Alzheimer's dementia.^[5] The drug also missed efficacy goals for Huntington's disease.^[6]^[7]

References

^ Adlard, Paul A.; Cherny, Robert A.; Finkelstein, David I.; Gautier, Elisabeth; Robb, Elysia; Cortes, Mikhalina; Volitakis, Irene; Liu, Xiang; et al. (2008). "Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs is Associated with Decreased Interstitial Aβ". Neuron. 59 (1): 43–55. doi:10.1016/j.neuron.2008.06.018. PMID 18614028.
^ Duce, James A.; Tsatsanis, Andrew; Cater, Michael A.; James, Simon A.; Robb, Elysia; Wikhe, Krutika; Leong, Su Ling; Perez, Keyla; et al. (2010). "Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer's Disease". Cell. 142 (6): 857–67. doi:10.1016/j.cell.2010.08.014. PMC 2943017. PMID 20817278. {{cite journal}}: Unknown parameter |laydate= ignored (help); Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help)
^ "Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study". Bloomberg News. Mar 31, 2014.
^ "PBT2 Takes a Dive in Phase 2 Alzheimer's Trial". April 2014.
^ "There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementia". Cochrane Database of Systematic Reviews: Plain Language Summaries. PubMed Health.
^ "Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles". thestreet.com.
^ Huntington Study Group Reach2HD Investigators (2015). "Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial". The Lancet Neurology. 14 (1): 39–47. doi:10.1016/S1474-4422(14)70262-5. PMID 25467848.{{cite journal}}: CS1 maint: numeric names: authors list (link)

[1] Adlard, Paul A.; Cherny, Robert A.; Finkelstein, David I.; Gautier, Elisabeth; Robb, Elysia; Cortes, Mikhalina; Volitakis, Irene; Liu, Xiang; et al. (2008). "Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs is Associated with Decreased Interstitial Aβ". Neuron. 59 (1): 43–55. doi:10.1016/j.neuron.2008.06.018. PMID 18614028.

[2] Duce, James A.; Tsatsanis, Andrew; Cater, Michael A.; James, Simon A.; Robb, Elysia; Wikhe, Krutika; Leong, Su Ling; Perez, Keyla; et al. (2010). "Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer's Disease". Cell. 142 (6): 857–67. doi:10.1016/j.cell.2010.08.014. PMC 2943017. PMID 20817278. {{cite journal}}: Unknown parameter |laydate= ignored (help); Unknown parameter |laysource= ignored (help); Unknown parameter |laysummary= ignored (help)

[3] "Prana Biotech Plunges 76%; Drug Fails in Alzheimer Study". Bloomberg News. Mar 31, 2014.

[4] "PBT2 Takes a Dive in Phase 2 Alzheimer's Trial". April 2014.

[5] "There is no evidence that MPACs (PBT1 or PBT2) are of benefit in Alzheimer's dementia". Cochrane Database of Systematic Reviews: Plain Language Summaries. PubMed Health.

[6] "Prana Bio Huntington's Disease Drug Fails Key Efficacy Hurdles". thestreet.com.

[7] Huntington Study Group Reach2HD Investigators (2015). "Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial". The Lancet Neurology. 14 (1): 39–47. doi:10.1016/S1474-4422(14)70262-5. PMID 25467848.{{cite journal}}: CS1 maint: numeric names: authors list (link)

[1]

[2]

[3]

[4]

[5]

[6]

[7]